Edition:
United States

People: Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

5.75USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$5.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
139,608
52-wk High
$14.62
52-wk Low
$4.92

Kerr, Giles 

Mr. Giles F. B. Kerr has been appointed as Independent Non-Executive Director of the Company, effective from November 1, 2016. Mr. Kerr also serves as a member of the Audit Committee. Giles Kerr has substantial commercial and financial experience gained from service on numerous public and private company boards and as an audit partner. He has served as Director of Finance of the University of Oxford since 2005. He also currently serves as a Board member of public companies BTG plc (LSE: BTG), Paypoint plc (LSE: PAY) and Senior plc (LSE: SNR) as well as several private companies. Mr. Kerr previously served as Chief Financial Officer and a Board member of Amersham plc, until its acquisition by GE Healthcare in 2004, and as a director of Victrex plc and Elan Corporation Inc. Prior to his role at Amersham, he was a National Partner with Arthur Andersen. Mr. Kerr is an economics graduate of the University of York, U.K., and a Fellow of the Institute of Chartered Accountants of England and Wales.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --